GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surface Oncology Inc (NAS:SURF) » Definitions » EPS without NRI

Surface Oncology (Surface Oncology) EPS without NRI : $-1.53 (TTM As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Surface Oncology EPS without NRI?

Surface Oncology's earnings per share without non-recurring items for the three months ended in Jun. 2023 was $-0.46. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.53.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Surface Oncology's EPS without NRI or its related term are showing as below:

SURF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -75   Med: -29.6   Max: 16.7
Current: 16.7

SURF's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 5.1 vs SURF: 16.70

Surface Oncology's EPS (Diluted) for the three months ended in Jun. 2023 was $-0.46. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.53.

Surface Oncology's EPS (Basic) for the three months ended in Jun. 2023 was $-0.46. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.53.


Surface Oncology EPS without NRI Historical Data

The historical data trend for Surface Oncology's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surface Oncology EPS without NRI Chart

Surface Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS without NRI
Get a 7-Day Free Trial -0.33 -1.97 1.57 -1.77 -1.14

Surface Oncology Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.46 -0.39 -0.35 -0.33 -0.46

Competitive Comparison of Surface Oncology's EPS without NRI

For the Biotechnology subindustry, Surface Oncology's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surface Oncology's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Surface Oncology's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Surface Oncology's PE Ratio without NRI falls into.



Surface Oncology EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Surface Oncology  (NAS:SURF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Surface Oncology EPS without NRI Related Terms

Thank you for viewing the detailed overview of Surface Oncology's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Surface Oncology (Surface Oncology) Business Description

Traded in Other Exchanges
N/A
Address
50 Hampshire Street, 8th Floor, Cambridge, MA, USA, 02139
Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors in the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out throughout the region of the United States.
Executives
Chandra Adams officer: Deputy GC SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Alison Oneill officer: Chief Medical Officer
Jessica Fees officer: See Remarks C/O SURFACE ONCOLOGY, ICN., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Robert W. Ross officer: Chief Medical Officer C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Henry C. Rath officer: Chief Business Officer C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FL, CAMBRIDGE MA 02139
Vito J. Palombella officer: Chief Scientific Officer 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Carsten Brunn director C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Theresa Boni officer: General Counsel C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Benjamin Hickey director C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Liisa I Nogelo officer: General Counsel C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Jeff Goater director, officer: Chief Executive Officer C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
David S. Grayzel director C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Ix, L.p. 10 percent owner 46 WAREHAM STREET, FLOOR 3, BOSTON MA 02118
Atlas Venture Associates Ix, Llc 10 percent owner 56 WAREHAM STREET, FLOOR 3, BOSTON MA 02118